Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Saf. 2008 Sep;7(5):515-23. doi: 10.1517/14740338.7.5.515 .

Safety of ceftriaxone sodium at extremes of age.

Author information

1
Diabetes and Cardiovascular Research, CPL Associates, LLC, 3980 Sheridan Drive, Amherst, NY 14226, USA. smonte@cplassociates.com

Abstract

BACKGROUND:

Isolated reports of neonatal and infant deaths associated with ceftriaxone-calcium precipitation in the lungs and kidneys have prompted a recommendation from the US FDA in June 2007 advising that in patients of all ages, calcium-containing solutions should not be administered simultaneously or within 48 h of the last ceftriaxone dose.

OBJECTIVE:

To provide a comprehensive review of the literature surrounding the safety of ceftriaxone in the neonatal (< or = 28 days) and geriatric populations (> or = 65 years).

METHODS:

Multi-database literature search for original research articles, review articles and case reports pertaining to safety of ceftriaxone in the neonatal and geriatric populations.

RESULTS/CONCLUSIONS:

Ceftriaxone should be avoided or significantly minimized in neonates (especially those treated concomitantly with intravenous calcium solutions and those with hyperbilirubinemia), and potentially restricted in the geriatric population treated concomitantly with intravenous calcium.

PMID:
18759704
DOI:
10.1517/14740338.7.5.515
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center